Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age

References

• BrantonMH, SchiffmannR, SabnisSG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81(2):122–138. doi:10.1097/00005792-200203000-0000311889412
   PubMed Web of Science ®Google Scholar
• MehtaA, RicciR, WidmerU, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236–242. doi:10.1111/j.1365-2362.2004.01309.x15025684
   PubMed Web of Science ®Google Scholar
• KampmannC, BaehnerF, WhybraC, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol. 2002;40(9):1668–1674. doi:10.1016/s0735-1097(02)02380-x12427421
   PubMed Web of Science ®Google Scholar
• LinhartA, KampmannC, ZamoranoJL, et al. Cardiac manifestations of Anderson–Fabry disease: results from the international Fabry Outcome Survey. Eur Heart J. 2007;28(10):1228–1235. doi:10.1093/eurheartj/ehm15317483538
   PubMed Web of Science ®Google Scholar
• ReisinR, PerrinA, García‐PavíaP. Time delays in the diagnosis and treatment of Fabry disease. Int J Clin Pract. 2017;71(1). doi:10.1111/ijcp.12914
   PubMed Web of Science ®Google Scholar
• DesnickRJ, BradyR, BarrangerJ, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138(4):338–346. doi:10.7326/0003-4819-138-4-200302180-0001412585833
   PubMed Web of Science ®Google Scholar
• GermainDP, CharrowJ, DesnickRJ, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353–358. doi:10.1136/jmedgenet-2014-10279725795794
   PubMed Web of Science ®Google Scholar
• WeidemannF, NiemannM, StörkS, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274(4):331–341. doi:10.1111/joim.1207723586858
   PubMed Web of Science ®Google Scholar
• BiegstraatenM, ArngrimssonR, BarbeyF, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36. doi:10.1186/s13023-015-0253-625885911
   PubMed Web of Science ®Google Scholar
• WhybraC, KampmannC, KrummenauerF, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65(4):299–307. doi:10.1111/j.1399-0004.2004.00219.x15025723
   PubMed Web of Science ®Google Scholar
• Kidney Disease Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.
   Web of Science ®Google Scholar
• WalkerHK, HallWD, HurstJW. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Boston, MD: Butterworths; 1990.
   Google Scholar
• de SimoneG, DevereuxRB, DanielsSR, KorenMJ, MeyerRA, LaraghJH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995;25(5):1056–1062. doi:10.1016/0735-1097(94)00540-77897116
   PubMed Web of Science ®Google Scholar
• BreunigF, WeidemannF, StrotmannJ, KnollA, WannerC. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 2006;69(7):1216–1221. doi:10.1038/sj.ki.500020816609685
   PubMed Web of Science ®Google Scholar
• GermainDP, WaldekS, BanikazemiM, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18(5):1547–1557. doi:10.1681/ASN.200608081617409312
   PubMed Web of Science ®Google Scholar
• BeckM, HughesD, KampmannC, et al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis. Mol Genet Metab Rep. 2015;3:21–27. doi:10.1016/j.ymgmr.2015.02.00226937390
   PubMed Web of Science ®Google Scholar
• ArendsM, WannerC, HughesD, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631–1641. doi:10.1681/ASN.201609096427979989
   PubMed Web of Science ®Google Scholar
• SchiffmannR, WarnockDG, BanikazemiM, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24(7):2102–2111. doi:10.1093/ndt/gfp03119218538
   PubMed Web of Science ®Google Scholar
• CohenE, NardiY, KrauseI, et al. A longitudinal assessment of the natural rate of decline in renal function with age. J Nephrol. 2014;27(6):635–641. doi:10.1007/s40620-014-0077-924643437
   PubMed Web of Science ®Google Scholar
• KampmannC, PerrinA, BeckM. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment. Orphanet J Rare Dis. 2015;10:125. doi:10.1186/s13023-015-0338-226416388
   PubMed Web of Science ®Google Scholar
• KampmannC, LinhartA, BaehnerF, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol. 2008;130(3):367–373. doi:10.1016/j.ijcard.2008.03.00718572264
   PubMed Web of Science ®Google Scholar
• WuJC, HoCY, SkaliH, et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J. 2010;31(9):1088–1097. doi:10.1093/eurheartj/ehp58820061327
   PubMed Web of Science ®Google Scholar
• GermainDP, WeidemannF, AbioseA, et al. Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry. Genet Med. 2013;15(12):958–965. doi:10.1038/gim.2013.5323703683
   PubMed Web of Science ®Google Scholar